First Allied Advisory Services’s United Therapeutics UTHR Stock Holding History

First Allied Advisory Services’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,495	Closed	-$620K	–	1243
2018 Q2	$620K	Buy	5,495 +178	+3%	+$19.6K	0.02%	602
2018 Q1	$596K	Sell	5,317 -360	-6%	-$45.7K	0.02%	613
2017 Q4	$842K	Buy	5,677 +758	+15%	+$96.4K	0.03%	493
2017 Q3	$580K	Buy	4,919 +340	+7%	+$43.4K	0.03%	567
2017 Q2	$598K	Buy	4,579 +19	+0.4%	+$2.37K	0.03%	556
2017 Q1	$618K	Buy	4,560 +182	+4%	+$27.6K	0.03%	510
2016 Q4	$628K	Sell	4,378 -1,858	-30%	-$237K	0.03%	514
2016 Q3	$736K	Buy	6,236 +2,330	+60%	+$280K	0.04%	445
2016 Q2	$412K	Sell	3,906 -199	-5%	-$22.2K	0.02%	617
2016 Q1	$461K	Sell	4,105 -194	-5%	-$24.5K	0.03%	570
2015 Q4	$672K	Buy	+4,299	New	+$626K	0.03%	480

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Allied Advisory Services's UTHR Position: Q3 2018 in Review

First Allied Advisory Services sold out of United Therapeutics (UTHR) in Q3 2018, closing a stake of 5,495 shares — an estimated $620K sold.

First Allied Advisory Services first reported a position in UTHR in Q4 2015 and held it in 11 quarters. The position peaked at $842K in Q4 2017. 367 funds tracked by Wall St. Rank hold UTHR as of Q3 2018.

First Allied Advisory Services reported no remaining United Therapeutics position as of Q3 2018 after selling out during the quarter.
First Allied Advisory Services sold 5,495 United Therapeutics shares in Q3 2018, an estimated $620K.
First Allied Advisory Services first reported a position in United Therapeutics in Q4 2015 and held it in 11 quarters.
First Allied Advisory Services's United Therapeutics position peaked at $842K in Q4 2017.
367 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2018.

Based on First Allied Advisory Services's 13F filing for Q3 2018, filed 14 Nov 2018.